Table 2.
Side effects follow-up assessment.
| Follow-Up Variable | CAF | PLA | p-Value |
|---|---|---|---|
| Dizziness | 0.76 ± 1.075 | 0.35 ± 0.812 | 0.003 * |
| Headache | 0.44 ± 0.991 | 0.35 ± 0.774 | 0.608 |
| Fast/Racing Heart Rate | 1.79 ± 1.338 | 1.74 ± 1.421 | 0.754 |
| Heart Skipping/Palpitations | 0.24 ± 0.699 | 0.15 ± 0.558 | 0.586 |
| Shortness of Breath | 1.32 ± 1.364 | 1.26 ± 1.483 | 0.494 |
| Nervousness | 0.59 ± 1.048 | 0.35 ± 0.849 | 0.304 |
| Blurred Vision | 0.26 ± 0.618 | 0.09 ± 0.288 | 0.084 |
Side effects assessment data are presented in means ± standard deviations and p-values between treatment groups (CAF vs. PLA). * denotes significant difference between conditions (CAF vs. PLA).